Kerri Fitzgerald

DocwireNews

Observational studies have reported &ldquo;higher-than-expected&rdquo; discontinuation rates for biosimilar monoclonal antibodies related to the &ldquo;nocebo&rdquo; effect&mdash;the perceived induction/worsening of symptoms or loss of effect induced by switching to a biosimilar agent. A study published in <a href="In%20observational%20studies%20of%20patients%20switched%20from%20stable%20treatment%20with%20an%20originator%20monoclonal%20antibody%20(mAb)%20to%20a%20biosimilar,%20higher%20rates%20of%20biosimilar%20discontinuation%20versus%20those%20observed%20in%20blinded%20switching%20studies%20have%20been%20reported.%20Because%20this%20observation%20relates%20to%20the%20real-world%20setting,%20it%20has%20been%20suggested%20that%20switching%20outside%20of%20clinical%20trials%20may%20be%20associated%20with%20nocebo%20effects.%20However,%20real-world%20data%20on%20drug%20discontinuation%20and%20nocebo%20effects%20after%20switching%20to%20mAb%20biosimilars%20remain%20limited.%20This%20systematic%20review%20collated%20information%20from%20switching%20studies%20regarding%20discontinuation%20rates%20of%20biosimilar%20mAbs%20and%20investigated%20the%20subjectivity%20of%20reasons%20for%20discontinuation%20to%20determine%20the%20impact%20of%20potential%20nocebo%20responses.">Clinical Therapeutics</a> supported previous studies, indicating that subjective effects may increase discontinuation rates among patients receiving biosimilar monoclonal antibodies.Researchers conducted a systematic review of Medline, EMBASE, Chochrane Library, and abstract databases of select conferences to identify studies that involved at least one treatment switch from an originator therapeutic monoclonal antibody. They included studies with a minimum post-switch follow-up of 6 months or more and accessible information on discontinuation rates. Researchers excluded interventional and blinded clinical trials, &ldquo;as higher-than-expected discontinuation rates have been reported in the observational setting only,&rdquo; they said.Biosimilar monoclonal antibody discontinuation rates were analyzed per therapeutic indication and according to duration of post-switch follow-up, mean/median duration on originator product treatment, and calendar period of the switch. Researchers also assessed the subjectivity of reasons for discontinuation.A total of 14 observational English-language studies were included, all of which included a single, non-medical switch from the reference infliximab to the biosimilar infliximab, CT-P13. Discontinuation rates of the biosimilar agent ranged from 2.8% to 28.2% among the studies included. Eleven studies (78.6%) reported biosimilar discontinuation rates that were higher-than-expected based on data pertaining to long-term use of the originator infliximab and clinical trials involving a switch to CT-P13. The mean/median duration of treatment with the originator infliximab prior to a switch to CT-P13 varied from 2.9 to 17 years among the studies. Common reasons for discontinuation were lack of efficacy and adverse events (AEs).&ldquo;Because these higher discontinuation rates could be attributed, in part, to subjective disease worsening or subjective AEs, this observation may be indicative of potential nocebo effects in monoclonal antibody switching studies,&rdquo; the researchers noted. &ldquo;These findings highlight the need for further patient education and well-designed, observational switching studies as well as the collection and analysis of identifiable pharmacovigilance and post-marketing data of biologics, including biosimilars.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

“Nocebo” Affect and Biosimilar Discontinuation Rates

Oncology

Observational studies have reported “higher-than-expected” discontinuation rates for biosimilar monoclonal antibodies related to the “nocebo” effect—the perceived ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe